Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.35 |
| ▸ | THPO | P40225 | 2/20 | 0.35 |
| ▸ | GMNN | O75496 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | STAT6 | P42226 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8003854 | 1.00 | MAPK1 (0.35) | MAPK1NPSR1TP53NFKB1THPO | |
| SCHEMBL17541903 | 0.87 | MAPK1 (0.34) | MAPK1NPSR1TP53NFKB1THPO | |
| SCHEMBL19747687 | 0.82 | MAPK1 (0.31) | MAPK1NPSR1TP53NFKB1THPO | |
| SCHEMBL11851494 | 0.78 | MAPK1 (0.38) | MAPK1NPSR1TP53NFKB1THPO | |
| SCHEMBL19550764 | 0.75 | MAPK1 (0.33) | MAPK1NPSR1MEN1GAAKMT2A | |
| SCHEMBL19550763 | 0.75 | MAPK1 (0.33) | MAPK1NPSR1MEN1GAAKMT2A | |
| SCHEMBL19550825 | 0.75 | MAPK1 (0.33) | MAPK1NPSR1MEN1GAAKMT2A | |
| SCHEMBL8016106 | 0.75 | G6PD (0.32) | — | |
| SCHEMBL23483851 | 0.74 | HSD11B1 (0.31) | MAPK1NPSR1TP53NFKB1THPO | |
| SCHEMBL30001364 | 0.74 | HSD11B1 (0.31) | MAPK1NPSR1TP53NFKB1THPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112225767-A | High-selectivity synthesis method of gemcitabine intermediate | 苏州华鑫医药科技有限公司 | 2021-01-15 | — | — | CN | claimed |
| CN-112079891-A | Preparation method of antitumor drug gemcitabine hydrochloride | 苏州华鑫医药科技有限公司 | 2020-12-15 | — | — | CN | claimed |
| CN-111732562-A | Preparation method of intermediate of antitumor drug gemcitabine hydrochloride | 苏州华鑫医药科技有限公司 | 2020-10-02 | — | — | CN | claimed |
| CN-112225767-A | High-selectivity synthesis method of gemcitabine intermediate | 苏州华鑫医药科技有限公司 | 2021-01-15 | — | — | CN | disclosed |
| CN-112079891-A | Preparation method of antitumor drug gemcitabine hydrochloride | 苏州华鑫医药科技有限公司 | 2020-12-15 | — | — | CN | disclosed |
| CN-111732562-A | Preparation method of intermediate of antitumor drug gemcitabine hydrochloride | 苏州华鑫医药科技有限公司 | 2020-10-02 | — | — | CN | disclosed |
| EP-3452466-B1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2020-08-12 | — | — | EP | disclosed |
| EP-3452466-A1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | Amgen Inc. (US) | 2019-03-13 | — | — | EP | disclosed |
| US-10150760-B2 | Compounds for use in preparing heterocyclic triazole agonists of the APJ receptor | AMGEN INC. (US) | 2018-12-11 | — | — | US | disclosed |
| US-20180222895-A1 | COMPOUNDS FOR USE IN PREPARING HETEROCYCLIC TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2018-08-09 | — | — | US | disclosed |
| US-9988369-B2 | Heterocyclic triazole compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2018-06-05 | — | — | US | disclosed |
| WO-2017192485-A1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2017-11-09 | — | — | WO | disclosed |
| CN-1111410-C | The preparation of drug combination method | PFIZER (US) | 2003-06-18 | — | — | CN | disclosed |
| CN-1061046-C | Process for preparing cephalosporin derivatives | PFIZER (US) | 2001-01-24 | — | — | CN | disclosed |
| US-6077952-A | Cephaloporins and homologues | PFIZER INC. (US) | 2000-06-20 | — | — | US | disclosed |
| US-6020329-A | Cephaloporins and homologues, preparations and pharmaceutical compositions | PZIFER INC. (US) | 2000-02-01 | — | — | US | disclosed |
| US-6001997-A | Cephalosporins and homologues, preparations and pharmaceutical compositions | BATESON JOHN HARGREAVES (GB) | 1999-12-14 | — | — | US | disclosed |
| CN-1223859-A | Process for preparation of pharmaceutical composition | PFIZER (US) | 1999-07-28 | — | — | CN | disclosed |
| CN-1060469-A | Process for preparing cephalosporin derivatives | BEECHAM GROUP PLC (GB) | 1992-04-22 | — | — | CN | disclosed |
| WO-1992001696-A1 | CEPHALOSPORINS AND HOMOLOGUES, PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS | BEECHAM GROUP PLC (GB) | 1992-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222895-A1 | COMPOUNDS FOR USE IN PREPARING HETEROCYCLIC TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, APLNR, GPR27 | MAPK1 1166/4885NPSR1 169/4885TP53 4129/4885 |
| US-10150760-B2 | Compounds for use in preparing heterocyclic triazole agonists of the APJ receptor | TBXA2R, APLNR, GPR27 | MAPK1 1166/4885NPSR1 169/4885TP53 4129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.